Viability assessment with MRI is superior to FDG-PET for viability: Pro.
Maddahi
Jamshid
J
Department of Molecular and Medical Pharmacology, Division of Nuclear Medicine, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, 90095-7064, USA. jmaddahi@mednet.ucla.edu
D003287:Contrast Media / Q000494:pharmacology; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging; D019788:Fluorodeoxyglucose F18 / Q000494:pharmacology*; D006321:Heart / Q000000981:diagnostic imaging / Q000503:physiopathology*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009206:Myocardium / Q000473:pathology*; D010477:Perfusion; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left
D003287:Contrast Media; D019788:Fluorodeoxyglucose F18